Federal Register / Vol. 63, No. 130 /Wednesday, July 8, 1998 / Notices 36911

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than July 31, 1998.

A. Federal Reserve Bank of Atlanta

(Lois Berthaume, Vice President) 104

Marietta Street, N.W., Atlanta, Georgia

30303-2713:

1. First American Corporation,

Nashville, Tennessee; to merge with

CSB Financial Corporation, Ashland

City, Tennessee, and thereby indirectly

acquire Cheatham State Bank, Kingston

Springs, Tennessee.

Board of Governors of the Federal Reserve

System, July 2, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–18092 Filed 7–7–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in

Permissible Nonbanking Activities or

to Acquire Companies that are

Engaged in Permissible Nonbanking

Activities

The companies listed in this notice

have given notice under section 4 of the

Bank Holding Company Act (12 U.S.C.

1843) (BHC Act) and Regulation Y, (12

CFR Part 225) to engage de novo, or to

acquire or control voting securities or

assets of a company, including the

companies listed below, that engages

either directly or through a subsidiary or

other company, in a nonbanking activity

that is listed in § 225.28 of Regulation

Y (12 CFR 225.28) or that the Board has

determined by Order to be closely

related to banking and permissible for

bank holding companies. Unless

otherwise noted, these activities will be

conducted throughout the United States.

Each notice is available for inspection

at the Federal Reserve Bank indicated.

The notice also will be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether the proposal complies

with the standards of section 4 of the

BHC Act.

Unless otherwise noted, comments

regarding the applications must be

received at the Reserve Bank indicated

or the offices of the Board of Governors

not later than July 22, 1998.

A. Federal Reserve Bank of Atlanta

(Lois Berthaume, Vice President) 104

Marietta Street, N.W., Atlanta, Georgia

30303-2713:

1. The Colonial BancGroup, Inc.,

Montgomery, Alabama; to acquire

ProImage, Inc., Macon, Georgia, and

thereby engage in data processing

activities, pursuant to § 225.28(b)(14) of

Regulation Y.

Board of Governors of the Federal Reserve

System, July 2, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–18093 Filed 7–7–98; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Announcement Number 99003]

Applied Research Program in

Emerging Infections Investigations of

Infectious Causes of Chronic

Diseases; Notice of Availability of

Funds for Fiscal Year 1999

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1999

funds for competitive grants and/or

cooperative agreements to support

applied research on emerging infections.

This announcement specifically

addresses infectious causes of chronic

diseases.

CDC is committed to achieving the

health promotion and disease

prevention objectives of Healthy People

2000, a national activity to reduce

morbidity and mortality and improve

the quality of life. This announcement

is related to the priority area of

Immunization and Infectious Diseases.

(For ordering a copy of Healthy People

2000, see the section Where to Obtain

Additional Information.)

Authority

This program is authorized under

sections 301(a) and 317(k)(2) of the

Public Health Service Act, as amended

[42 U.S.C. 241(a) and 247b(k)(2)].

Smoke-Free Workplace

CDC strongly encourages all grant

recipients to provide a smoke-free

workplace and to promote the non-use

of all tobacco products, and Public Law

103–227, the Pro-Children’s Act of 1994,

prohibits smoking in certain facilities

that receive Federal funds in which

education, library, day-care, health-care

and early childhood development

services are provided to children.

Eligible Applicants

Applications may be submitted by

public and private nonprofit

organizations and governments and

their agencies. Thus, universities,

colleges, research institutions, hospitals,

other public and private nonprofit

organizations, including State and local

governments or their bona fide agents,

federally recognized Indian tribal

governments, Indian tribes or Indian

tribal organizations are eligible to apply.

Note: Only one application will be

accepted from any single applicant,

organization, government, or agency.

Availability of Funds

Approximately $500,000 is available

in FY 1999 to fund one to three awards.

It is expected that the average award

will be $500,000, ranging from $100,000

to $500,000. It is expected the award(s)

will begin on or about March 1, 1999,

and will be made for a 12-month budget

period within a project period of up to

three years. (These funding amounts are

for the first 12-month budget period and

include both direct and indirect costs.)

Funding estimates may vary and are

subject to change.

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress and

availability of funds.

Determination of Which Instrument to

Use

Applicants must specify the type of

award for which they are applying,

either grant or cooperative agreement.

CDC will review the applications in

accordance with the evaluation criteria.

Before issuing awards, CDC will

determine whether a grant or

cooperative agreement is the

appropriate instrument based upon the

need for substantial CDC involvement in

the project.
36912 Federal Register / Vol. 63, No. 130 /Wednesday, July 8, 1998 / Notices

To assist applicants in making a

determination as to which type of award

to apply for, the following information

is provided:

1. Grants

A research project grant is one in

which substantial programmatic

involvement by CDC is not anticipated

by the recipient during the project

period. Applicants for grants must

demonstrate an ability to conduct the

proposed research with minimal

assistance, other than financial support,

from CDC. This would include

possessing sufficient resources for

clinical, laboratory, and data

management services and a level of

scientific expertise to achieve the

objectives described in their research

proposal without substantial technical

assistance from CDC.

2. Cooperative Agreements

A research project cooperative

agreement is one in which CDC will

assist recipients in conducting the

proposed research. The application

should be presented in a manner that

demonstrates the applicant’s ability to

address the research problem in a

collaborative manner with CDC.

Use of Funds

Restrictions on Lobbying

Applicants should be aware of

restrictions on the use of HHS funds for

lobbying of Federal or State legislative

bodies. Under the provisions of 31

U.S.C. section 1352 (which has been in

effect since December 23, 1989),

recipients (and their subtier contractors)

are prohibited from using appropriated

Federal funds (other than profits from a

Federal contract) for lobbying Congress

or any Federal agency in connection

with the award of a particular contract,

grant, cooperative agreement, or loan.

This includes grants/cooperative

agreements that, in whole or in part,

involve conferences for which Federal

funds cannot be used directly or

indirectly to encourage participants to

lobby or to instruct participants on how

to lobby.

In addition, the FY 1998 Department

of Labor, Health and Human Services,

and Education, and Related Agencies

Appropriations Act (Public Law 105–78)

states in sections 503(a) and (b) that no

part of any appropriation contained in

this Act shall be used, other than for

normal and recognized executivelegislative relations, for publicity or

propaganda purposes, for the

preparation, distribution, or use of any

kit, pamphlet, booklet, publication,

radio, television, or video presentation

designed to support or defeat legislation

pending before the Congress or any

State legislature, except in presentation

to the Congress or any State legislature

itself. No part of any appropriation

contained in this Act shall be used to

pay the salary or expenses of any grant

or contract recipient, or agent acting for

such recipient, related to any activity

designed to influence legislation or

appropriations pending before the

Congress or any State legislature.

Background

In the United States (U.S.) and

elsewhere, infectious diseases continue

to threaten public health and contribute

to the escalating costs of health care.

While infectious diseases remain the

leading cause of death in developing

countries, the burden of illness and

death due to chronic medical conditions

has surpassed the role of infectious

diseases in most industrialized

countries. However, an increasing body

of evidence now suggests that infectious

agents play critical roles in several

chronic diseases, including major

problems such as cancer, heart disease,

and diabetes mellitus. The emerging

role of micro-organisms as etiologies for

chronic diseases has important

implications for therapy, prevention,

and pathogenesis, and this topic merits

research efforts designed with the

public health implications of these new

associations kept in mind.

Over the past decade, causative roles

have been proposed or established for

infectious agents in conditions as

diverse as: duodenal ulcers and gastric

cancer; juvenile onset diabetes mellitus;

atherosclerosis; Kaposi’s sarcoma;

Guillain-Barre syndrome; Crohn’s

disease; cerebral palsy; preterm low

birth weight, and infertility. The burden

of evidence supporting some of these

associations has been sufficient to

introduce intervention trials (e.g.,

Chlamydia pneumoniae and

atherosclerosis) and even consensus

treatment standards (e.g., Helicobacter

pylori and peptic ulcer disease), while

other associations remain speculative at

present. The fraction of a given chronic

disease which can be attributed to

specific infectious agents is unknown

for the majority of conditions for which

an association is now considered likely.

Further, although several specific

infections are now recognized causes of

pre-term low birth weight, the

proportion of infants born prematurely

as a result of infectious diseases is not

known, nor is the proportion of these

occurrences which can be prevented

through appropriate screening and

treatment of infections prenatally.

CDC has developed a plan for

revitalizing the nation’s ability to

identify, contain, and prevent illness

from emerging infectious diseases

(Addressing Emerging Infectious

Diseases Threats: A Prevention Strategy

for the U.S). The plan includes applied

research as a major objective, stressing

the importance of integrating laboratory

science and epidemiology to optimize

public health practice in the U.S. CDC

has developed an Extramural Applied

Research Program in Emerging

Infections (EARP) designed to fill gaps

in existing support for research in

emerging infectious disease

surveillance, epidemiology, and

prevention. This announcement

specifically addresses investigations of

infectious causes of chronic diseases

and solicits applications in this area.

For additional reading on this topic,

the following article is recommended:

Lorber B. Are All Diseases Infectious?

Ann Intern Med 1996;125:844–851.

Purpose

The purpose of the EARP is to provide

financial and technical assistance for

applied research projects on emerging

infections in the U.S. As a component

of EARP, the purpose of this grant/

cooperative agreement announcement is

to provide assistance for one or more

projects addressing infectious causes of

chronic diseases.

The objective is to address potential

associations between one or more

infectious agents and a chronic disease

syndrome by conducting an

investigation which either: (a) evaluates

a suspected relation between a specific

infectious agent and a chronic disease

syndrome; (b) designs and tests an

intervention strategy aimed at the

infection as a means of reducing chronic

disease sequelae; or (c) determines the

health burden of a chronic disease

attributable to the infectious agent. Note

that in addition to the standard chronic

disease syndromes such as cancer, heart

disease, diabetes, etc., syndromes that

may be addressed under this

announcement include preterm low

birth weight and infertility.

Program Requirements

In conducting activities to achieve the

purpose of this program, the recipient

will be responsible for the activities

under A. (Recipient Activities), and

CDC will be responsible for conducting

activities under B. (CDC Activities)

under cooperative agreements:

A. Recipient Activities

1. Develop a research protocol to

conduct one or more of the following

studies:
Federal Register / Vol. 63, No. 130 /Wednesday, July 8, 1998 / Notices 36913

a. Evaluate a suspected association

between one or more infections and a

chronic disease syndrome.

b. Develop, implement, and evaluate

a prevention strategy for reducing a

chronic disease by addressing the

associated infectious agent.

c. Determine the health burden of a

chronic disease attributable to an

associated infectious agent.

2. Conduct the proposed study using

a pilot phase, where appropriate, to

identify potential problems and make

modifications to the research protocol.

3. Publish and/or otherwise

disseminate results of the project.

B. CDC Activities (Cooperative

Agreements)

1. Provide technical assistance in the

design and conduct of the research.

2. Perform selected laboratory tests, as

appropriate and necessary.

3. Participate in data management, the

analysis of research data, and the

interpretation and presentation of

research findings.

4. Provide biological materials (e.g.,

strains, reagents, etc.) as necessary for

studies.

Technical Reporting Requirements

Narrative progress reports are

required semiannually. The first

semiannual report is required with the

second year’s noncompeting

continuation application and should

cover program activities from the date of

award for reporting in the first year of

the project. The second semiannual

report is due 90 days after the end of

each budget period and should cover

activities from the date of previous

report. Progress reports should

summarize tasks completed, problems

encountered, and plans for continued

research activities. Reports should also

include copies of any publications

resulting from the project.

An original and two copies of a

Financial Status Report (FSR) are

required no later than 90 days after the

end of each budget period.

A final performance report and FSR

are due no later than 90 days after the

end of the project period. All reports are

to be submitted to the Grants

Management Branch, CDC.

Application

1. Pre-application Letter-of-Intent

In order to enable CDC to plan and

review applications submitted under

this Program Announcement, all parties

intending to submit applications are

requested to inform CDC of their

intention to do so as soon as possible

but not later than 30 business days prior

to the application due date. Notification

should include: (1) this program

Announcement Number 99003, (2)

name and address of institution, and (3)

name, address, and telephone number of

contact person. Notification can be

provided by facsimile, postal mail, or

electronic mail (E-mail) to Anne

Schuchat, M.D., National Center for

Infectious Diseases, Centers for Disease

Control and Prevention (CDC), 1600

Clifton Road, NE., Mailstop C–23,

Atlanta, GA 30333, Facsimile (404) 639–

3970, Internet acs1@cdc.gov.

2. Application Content

Applicants are strongly encouraged to

develop applications in accordance with

PHS Form 398 (Revised 5/95, OMB

Control Number 0925–0001)

information contained in this grant/

cooperative agreement announcement

and the instructions outlined below. In

order to ensure an objective, impartial,

and prompt review, applications must

conform to these instructions.

The original and five (5) complete

copies of the application must be

UNSTAPLED and UNBOUND. ALL

pages must be clearly numbered, and a

complete index to the application and

its appendices must be included. All

typewritten materials must be singlespaced, using a font no smaller than size

12. All supplemental pages of the

application (i.e., in addition to the 398

forms) must be on the 81⁄2′′ by 11′′ white

paper. All pages must be printed on

ONE side only, with at least 1’’ margins,

headers, and footers.

The application narrative must not

exceed 12 pages (excluding budget and

appendices). Unless indicated

otherwise, all information requested

below must appear in the narrative.

Materials or information that should be

part of the narrative will not be accepted

if placed in the appendices. The

application narrative must contain the

following sections in the order

presented below:

a. Abstract

Provide a brief (two pages maximum)

abstract of the project. Clearly identify

the project period proposed (not to

exceed maximum of 3 years as indicated

in Availability of Funds section).

Clearly identify the type of award that

is being applied for, grant or cooperative

agreement.

b. Background and Need

Discuss the background and need for

the proposed project. Demonstrate a

clear understanding of the purpose and

objectives of this program

announcement. Discuss and

demonstrate how the proposed project

addresses an important gap which is of

public health importance.

c. Capacity and Personnel

Describe applicant’s past experience

in conducting activities similar to that

being proposed. Describe applicant’s

resources, facilities, and professional

personnel that will be involved in

conducting the project. Include in an

appendix curriculum vitae for all

professional personnel involved with

the project. Describe plans for

administration of the project and

identify administrative resources/

personnel that will be assigned to the

project. Clearly identify specific

assigned responsibilities for all key

professional personnel. Provide in an

appendix letters of support from all key

participating non-applicant

organizations, individuals, etc. (if any),

which clearly indicate their

commitment to participate as described

in the operational plan. (Do not include

letters of support from CDC personnel—

they will not be accepted.)

d. Objectives and Technical Approach

Present specific objectives for the

proposed research which are

measurable and time-phased and are

consistent with the Purpose and

Recipient Activities of this

announcement. Present a detailed

operational plan for initiating and

conducting the research which clearly

and appropriately addresses these

objectives (if proposing a multi-year

project, provide a detailed description

of first-year activities and a brief

overview of subsequent-year activities).

Include a clear description of

applicant’s technical approach/methods

which are directly relevant to the above

objectives. Describe specific study

protocols or plans for the development

of study protocols. Describe the nature

and extent of collaboration with CDC (if

proposing a cooperative agreement)

and/or others during various phases of

the research. Describe in detail a plan

for evaluating progress toward achieving

process and outcome project objectives.

If the project will employ a particular

research subject population, describe

characteristics of the patient population

and how research in this subject group

will yield generalizable information.

Describe contingency plans which

acknowledge how the research will

address likely obstacles and assure that

the proposed task(s) can still be

completed. Include sample size

calculations where appropriate to assure

that measurable objectives can be

evaluated.
36914 Federal Register / Vol. 63, No. 130 /Wednesday, July 8, 1998 / Notices

e. Budget

Provide a line-item budget and

accompanying detailed, line-by-line

justification for the first year of the

project that demonstrates the request is

consistent with the purpose and

objectives of this program. If requesting

a multi-year project, provide estimated

total budget (direct plus indirect) for

subsequent years. If requesting funds for

any contracts, provide the following

information for each proposed contract:

(1) Name of proposed contractor, (2)

breakdown and justification for

estimated costs, (3) description and

scope of activities to be performed by

contractor, (4) period of performance,

and (5) method of contractor selection

(e.g., sole-source or competitive

solicitation).

f. Human Subjects

Whether or not exempt from DHHS

regulations, if the proposed project

involves human subjects, describe in an

appendix adequate procedures for the

protection of human subjects. Also,

ensure that women, racial and ethnic

minority populations are appropriately

represented in applications for research

involving human subjects.

Evaluation Criteria

The applications will be reviewed and

evaluated according to the following

criteria:

1. Background and Need (15 Points)

Extent to which applicant

demonstrates a clear understanding of

the background, purpose, and objectives

of the project and the extent to which

the proposed project addresses an area

of public health importance not

adequately addressed in ongoing

programs.

2. Capacity (30 Points)

Extent to which applicant describes

adequate resources and facilities (both

technical and administrative) for

conducting the project. Extent to which

applicant documents that professional

personnel involved in the project are

qualified and have past experience and

achievements in research related to that

proposed as evidenced by curriculum

vitae, publications, etc. If applicable,

extent to which applicant includes

letters of support from non-applicant

organizations, individuals, etc., and the

extent to which such letters clearly

indicate the author’s commitment to

participate as described in the

operational plan. If the proposed project

includes evaluation of health conditions

in a defined population, the extent to

which generalizations from this

particular study population to broader

populations can be made.

3. Objectives and Technical Approach

(55 Points Total)

a. Extent to which applicant describes

objectives of the proposed research

which are consistent with the purpose

of this announcement and which are

measurable and time-phased. (15 points)

b. Extent to which applicant presents

a detailed operational plan for initiating

and conducting the research which

clearly and appropriately addresses all

Recipient Activities. Extent to which the

plan clearly describes applicant’s

technical approach/methods for

conducting the proposed research and

extent to which the approach/methods

are appropriate and adequate to

accomplish the objectives. Extent to

which applicant describes specific

study protocols or plans for the

development of study protocols that are

appropriate for achieving project

objectives. Extent to which applicant

describes adequate and appropriate

collaboration with CDC (if proposing a

cooperative agreement) and/or others

during various phases of the project. If

the proposed project involves human

subjects, whether or not exempt from

HHS regulations, the extent to which

adequate procedures are described for

the protection of human subjects, and

extent to which protections appear

adequate that women, racial and ethnic

minority populations are appropriately

represented in applications involving

human research. (35 points)

c. Extent to which applicant provides

a detailed and adequate plan for

evaluating progress toward achieving

project process and outcome objectives.

(5 points)

4. Budget (Not Scored)

Extent to which the proposed budget

is reasonable, clearly justifiable, and

consistent with the intended use of

grant/cooperative agreement funds.

Executive Order 12372 Review

This program is not subject to

Executive Order 12372 Review.

Public Health System Reporting

Requirements

This program is not subject to the

Public Health System Reporting

Requirements.

Catalog of Federal Domestic Assistance

Number

The Catalog of Federal Domestic

Assistance Number is 93.283.

Other Requirements

Paperwork Reduction Act

Projects that involve the collection of

information from ten or more

individuals and funded by the grant/

cooperative agreement will be subject to

review and approval by the Office of

Management and Budget (OMB) under

the Paperwork Reduction Act.

Human Subjects

If the proposed project involves

research on human subjects, the

applicant must comply with the

Department of Health and Human

Services Regulations (45 CFR Part 46)

regarding the protection of human

subjects. Assurance must be provided to

demonstrate that the project will be

subject to initial and continuing review

by an appropriate institutional review

committee. The applicant will be

responsible for providing evidence of

this assurance in accordance with the

appropriate guidelines and form

provided in the application kit.

In addition to other applicable

committees, Indian Health Service (IHS)

institutional review committees also

must review the project if any

component of IHS will be involved or

will support the research. If the Native

American community is involved, its

Tribal government must also approve

that portion of the project applicable to

it.

Women, Racial and Ethnic Minorities

It is the policy of the CDC and the

Agency for Toxic Substances and

Disease Registry (ATSDR) to ensure that

individuals of both sexes and the

various racial and ethnic groups will be

included in CDC/ATSDR-supported

research projects involving human

subjects, whenever feasible and

appropriate. Racial and ethnic groups

are those defined in OMB Directive No.

15 and include American Indian or

Alaska Native, Asian, Black or African

American, Hispanic or Latino, Native

Hawaiian or Other Pacific Islander.

Applicants shall ensure that women,

racial and ethnic minority populations

are appropriately represented in

applications for research involving

human subjects. Where clear and

compelling rationale exist that inclusion

is inappropriate or not feasible, this

situation must be explained as part of

the application. This policy does not

apply to research studies when the

investigator cannot control the race,

ethnicity, and/or sex of subjects. Further

guidance to this policy is contained in

the Federal Register, Vol. 60, No. 179,

pages 47947–47951, and dated Friday,

September 15, 1995.
Federal Register / Vol. 63, No. 130 /Wednesday, July 8, 1998 / Notices 36915

Animal Subjects

If the proposed project involves

research on animal subjects, the

applicant must comply with the ‘‘PHS

Policy on Humane Care and Use of

Laboratory Animals by Awardee

Institutions.’’ An applicant organization

proposing to use vertebrate animals in

PHS-supported activities must file an

Animal Welfare Assurance with the

Office for Protection from Research

Risks at the National Institutes of

Health.

Application Submission and Deadline

Applicants are strongly encouraged to

submit the original and five complete

copies of application PHS Form 398

(Revised 5/95, OMB Control Number

0925–0001) to Sharron P. Orum, Grants

Management Officer, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE., Room 300,

Mailstop E–18, Atlanta, GA 30305, on or

before October 1, 1998.

1. Deadline: Applications shall be

considered as meeting the deadline if

they are either:

a. Received on or before the deadline

date; or

b. Sent on or before the deadline date

and received in time for submission to

the objective review group. (Applicants

must request a legibly dated U.S. Postal

Service postmark or obtain a legibly

dated receipt from a commercial carrier

or U.S. Postal Service. Private metered

postmarks shall not be acceptable as

proof of timely mailing.)

2. Late Applications: Applications

which do not meet the criteria in 1.a. or

1.b. above are considered late

applications. Late applications will not

be considered and will be returned to

the applicant.

Where To Obtain Additional

Information

To receive additional written

information and to request an

application kit, call 1–888–GRANTS (1–

888–472–6874). You will be asked to

leave your name and address and will

be instructed to identify the

Announcement number of interest.

(Please refer to Announcement Number

99003.) You will receive a complete

program description, information on

application procedures and application

forms.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from Oppie

M. Byrd, Grants Management Specialist,

Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention

(CDC), 255 East Paces Ferry Road, NE.,

Room 314, Mailstop E–18, Atlanta, GA

30305, telephone (404) 842–6546,

Facsimile (404) 842–6513, Internet

oxb3@cdc.gov. Programmatic technical

assistance may be obtained from Anne

Schuchat, M.D., National Center for

Infectious Diseases, Division of Bacterial

and Mycotic Diseases, Centers for

Disease Control and Prevention (CDC),

1600 Clifton Road, NE., Mailstop C–23,

Atlanta, GA 30333, telephone (404)

639–4720, Internet acs1@cdc.gov.

Please refer to Announcement

Number 99003 when requesting

information regarding this program.

You may obtain this announcement

from one of two Internet sites on the

actual publication date: CDC’s Home

Page at http://www.cdc.gov or at the

Government Printing Office Home Page

(including free on-line access to the

Federal Register at http://

www.access.gpo.gov).

Potential applicants may obtain a

copy of Healthy People 2000 (Full

Report, Stock No. 017–001–00474–0) or

Healthy People 2000 (Summary Report,

Stock No. 017–001–00473–1) referenced

in the Introduction through the

Superintendent of Documents,

Government Printing Office,

Washington, D.C. 20402–9325,

telephone (202) 512–1800.

Dated: July 1, 1998.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 98–18018 Filed 7–7–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Announcement Number 99005]

Applied Research Program in

Emerging Infections Correlation of

Environmental Monitoring of Microbial

Agents With Disease Control; Notice of

Availability of Funds for Fiscal Year

1999

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1999

funds for competitive grants and/or

cooperative agreements to support

applied research on emerging infections.

This announcement specifically

addresses the correlation of

environmental monitoring of microbial

agents with disease control.

CDC is committed to achieving the

health promotion and disease

prevention objectives of Healthy People

2000, a national activity to reduce

morbidity and mortality and improve

the quality of life. This announcement

is related to the priority area of

Immunization and Infectious Diseases.

(For ordering a copy of Healthy People

2000, see the section Where to Obtain

Additional Information.)

Authority

This program is authorized under

Sections 301(a) and 317(k)(2) of the

Public Health Service Act, as amended

[42 U.S.C. 241(a) and 247b(k)(2)].

Smoke-Free Workplace

CDC strongly encourages all grant

recipients to provide a smoke-free

workplace and to promote the non-use

of all tobacco products, and Public Law

103–227, the Pro-Children’s Act of 1994,

prohibits smoking in certain facilities

that receive Federal funds in which

education, library, day-care, health-care

and early childhood development

services are provided to children.

Eligible Applicants

Applications may be submitted by

public and private nonprofit

organizations and governments and

their agencies. Thus, universities,

colleges, research institutions, hospitals,

other public and private nonprofit

organizations, including State and local

governments or their bona fide agents

are eligible to apply.

Note: An organization described in Section

501(c)(4) of the Internal Revenue Code of

1986 which engages in lobbying activities

shall not be eligible to receive Federal funds

constituting an award, grant, contract, loan,

or any other form.

Only one application will be accepted

from any single applicant, organization,

government, or agency.

Availability of Funds

Approximately $500,000 is available

in FY 1999 to fund one to three awards,

ranging from $100,000 to $500,000. It is

expected the award(s) will begin on or

about March 1, 1999, and will be made

for a 12-month budget period within a

project period of up to three years. (The

funding amounts listed above are for the

first 12-month budget period and

include both direct and indirect costs.)

Funding estimates may vary and are

subject to change.

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress and

availability of funds.